Abstract 4340502: Genetic Screening of Farby Disease from TPMI Biobank in Middle Taiwan: Single Center Experiences

Introduction: The prevalence of Fabry disease (FD) of general population and what most common initial presentation of FD are unknown. In addition to clinical diagnosis, the TPMI (Taiwan Precision Medicine Initiative Program) Biobank offers an unparalleled opportunity to determine the prevalence of FD-causing pathogenic variants in an unselected hospital visiting adult population. Methods: All TPMI participants were genotyped using the Axiom Genome-Wide TWB 2.0 Array Plate (Affymetrix, Santa Clara, CA, USA). The hot spots of Fabry disease-causing pathogenic variants were identified as genetic defined Fabry disease according to ACMG criteria pathogenic or likely pathogenic. All the identified variant were been validated by Sanger sequencing. We compared with genetic defined Fabry disease patients with age and gender matching hospital patients by ratio 1:4 respectively. The clinical renal, cardiac, and neurological manifestation were analyzed. Results: There were 112 genetic defined Fabry disease patients, male vs female: 43 vs 69, found from 43,000 Subjects aged more than 20 in TPMI Biobank from June, 24, 2019 to May 12, 2021. Prevalence was 0.26%. Five different genotype were identified and one was classic genotype GLA: c.1228A>G (N=1), and other 4 were late-onset genotype: GLA: c.902G>A (N=2), GLA:c.1067G>C (N=3), GLA: c.427G>A (N=1), and majority GLA: c.639+919G>A (N=105) (Figure 1). Comparing with matched population (112 vs 448) showed no difference in clinical presentation, including tinnitus, hearing impairment, visual impairment, corneal opacity, heart failure, atrial fibrillation, stroke, chronic kidney disease, or end stage renal disease, but higher hypertrophic cardiomyopathy (HCM) as presentation was noted in genetic defined Fabry disease patient group (P=0.014) (Figure 2). Conclusion: The prevalence of genetic defined FD in hospital based biobank was high, 0.26%. The most significant different clinical manifestation is HCM, which might due to most common genetic type is cardiac variant type (GLA: c.639+919G>A, 93%).

Authors

Institutions

Publication Details

Journal
Circulation
Published
2025-11-03
DOI
https://doi.org/10.1161/circ.152.suppl_3.4340502
Primary Topic
Lysosomal Storage Disorders Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 4340502: Genetic Screening of Farby Disease from TPMI Biobank in Middle Taiwan: Single Center Experiences

Chih‐Hung Lai
Circulation
Lysosomal Storage Disorders Research
article

Abstract 4340502: Genetic Screening of Farby Disease from TPMI Biobank in Middle Taiwan: Single Center Experiences

Chih‐Hung Lai
article en

Abstract

Introduction: The prevalence of Fabry disease (FD) of general population and what most common initial presentation of FD are unknown. In addition to clinical diagnosis, the TPMI (Taiwan Precision Medicine Initiative Program) Biobank offers an unparalleled opportunity to determine the prevalence of FD-causing pathogenic variants in an unselected hospital visiting adult population. Methods: All TPMI participants were genotyped using the Axiom Genome-Wide TWB 2.0 Array Plate (Affymetrix, Santa Clara, CA, USA). The hot spots of Fabry disease-causing pathogenic variants were identified as genetic defined Fabry disease according to ACMG criteria pathogenic or likely pathogenic. All the identified variant were been validated by Sanger sequencing. We compared with genetic defined Fabry disease patients with age and gender matching hospital patients by ratio 1:4 respectively. The clinical renal, cardiac, and neurological manifestation were analyzed. Results: There were 112 genetic defined Fabry disease patients, male vs female: 43 vs 69, found from 43,000 Subjects aged more than 20 in TPMI Biobank from June, 24, 2019 to May 12, 2021. Prevalence was 0.26%. Five different genotype were identified and one was classic genotype GLA: c.1228A>G (N=1), and other 4 were late-onset genotype: GLA: c.902G>A (N=2), GLA:c.1067G>C (N=3), GLA: c.427G>A (N=1), and majority GLA: c.639+919G>A (N=105) (Figure 1). Comparing with matched population (112 vs 448) showed no difference in clinical presentation, including tinnitus, hearing impairment, visual impairment, corneal opacity, heart failure, atrial fibrillation, stroke, chronic kidney disease, or end stage renal disease, but higher hypertrophic cardiomyopathy (HCM) as presentation was noted in genetic defined Fabry disease patient group (P=0.014) (Figure 2). Conclusion: The prevalence of genetic defined FD in hospital based biobank was high, 0.26%. The most significant different clinical manifestation is HCM, which might due to most common genetic type is cardiac variant type (GLA: c.639+919G>A, 93%).

CirculationVol. 152(Suppl_3)
Taichung Veterans General Hospital (TW)
Openalex Percentile: Top 60%
Lysosomal Storage Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.